Doctors are sending out a warning after children as young as 10 years old are using drugs like Ozempic and Wegovy.

One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analog class, better ...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...

Nearly 4.4 million adult New Yorkers, or 30%, have obesity, but access to weight-loss medications varies based on a variety ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster ...

If you’re taking semaglutide for diabetes or weight loss, a new once-a-month injection could soon make it easier to stick to ...

While GLP-1 medications like Ozempic and Wegovy hold promise for both weight loss and diabetes management, their potential for accidental misuse requires caution.

Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight ...

Novo Nordisk asked US regulators to approve the drug for children ages 6 to 11. In the EU, it's available for adolescents as ...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of ...